Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions

Hematological Malignancies

Interventions

DRUG

Gilteritinib

Administration of Gilteritinib

Trial Locations (1)

CHU de NICE, Nice

All Listed Sponsors

lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT06992934 - Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors | Biotech Hunter | Biotech Hunter